Log In | Shopping Cart | Advanced Search
            
  • Home
  • Career
  • Distributors
  • Contact Us:
  • Email: crm@excellgen.com
Products
Modified mRNA
Encapsulated mRNA
mRNA Enzyme
SARS-CoV-2
Pseudovirus
Popular Products
Cancer Proteins
Antibodies
DNA Binding Proteins
Electrophoresis
Genome Engineering
Polymerases
Recombinases
Transcription Factors
Transfection
Services
Modified mRNA
Custom Cloning
Virus Production
Protein Purification
Protein Expression
Modified mRNA
 Previous 
 Return to List 
 Next 

SARS-CoV-2 Spike Glycoprotein mRNA, South Africa Variant, HexaPro Stabilized Trimer

Catalog #: EG-333


Please Choose:



Qty:

Product Name SARS-CoV-2 Spike Glycoprotein mRNA, Trimeric HexaPro South Africa variant
Description

This modified mRNA encodes the full-length SARS-CoV-2 spike glycoprotein, stabilized by several mutations: the polybasic S1/S2 cleavage site RRAR is mutated to GSAS (residues 682 to 685); and 6 additional proline substitutions: K986P, V987P, F817P, A892P, A899P and A942P, producing a more stable HexaPro variant. In addition, T4 foldon trimerization domain is added to the C-terminus. The resulting trimeric S glycoprotein will be in an antigenically optimal pre-fusion conformation. The South Africa variant has these mutations: has K417N, E484K and N501Y.

Features
  • 5' Cap: Capped with ARCA (Anti Reverse Cap Analog, m7(3'-O-methyl)-G(5')ppp(5')G, Cap 0) or CleanCap AG (m7G(5')ppp(5')(2'OMeA)pG, Cap 1)
  • 5’-UTR: derived from human alpha-globin RNA with an optimized Kozak sequence
  • Codon Optimization: Human
  • Mutations: K417N, E484K and N501Y; Furin site RRAR mutated to GSAS; HexaPro mutations (K986P, V987P, F817P, A892P, A899P and A942P) to ensure the S glycoprotein remains in an antigenically optimal pre-fusion conformation
  • Nucleotide Modifications: mRNA modified with both Pseudo-UTP and 5mCTP
  • 3’-UTR: comprises two sequence elements derived from the amino-terminal enhancer of split (AES) mRNA and the mitochondrial encoded 12S ribosomal RNA to confer RNA stability and high total protein expression.
  • PolyA: 180 nt
Sequence Available upon request.
Application Animal Vaccine Research (Not for human use)
Concentration ~1 μg/μl
Transfection Protocol Lipofectamine™ MessengerMAX™ Transfection Reagent Protocol
QC Agarose gel electrophoresis
Shipping Dry ice
Storage -80 oC

     
 Ask a Question 
 
 Home | Privacy Policy | Terms & Conditions | Online Price Policy | Shipping & Return

Copyright © 2007-2022  Excellgen, Inc. All rights reserved